Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
CL$98.32+2.72(+2.85%)Inflation Is Running Above 3%. These 3 Dividend Stocks Have the Pricing Power to Keep Up.10:17:41 AM ETMU$821.68-33.25(-3.89%)Micron and other chip stocks slip as election results strike at the core of data-center optimism10:17:00 AM ETSHEL$103.87-0.35(-0.34%)Shell Agrees to $1.45 Billion Sale of North West Shelf Stake10:16:15 AM ETQCOM$168.58+4.15(+2.52%)Qualcomm sat out the semiconductor rally. Can a SpaceX partnership change that?10:13:00 AM ETAVGO$328.66-3.43(-1.03%)One Wall Street Analyst Says This Stock Is the Best Way to Invest in Anthropic and OpenAI. He's Right.10:10:00 AM ETSNDK$1,072.28-54.24(-4.81%)Sandisk Is Retiring Its Own Stock At A Discount - Upgrade To Buy10:08:39 AM ETMSFT$552.87+32.09(+6.16%)If You Invest $1,000 in Microsoft Today, Here's What It Could Be Worth by 202910:06:14 AM ETORCL$126.39+0.17(+0.13%)Oracle stock in green despite reported $7B Tencent chip deal cancellation10:03:17 AM ETAAPL$352.91+21.27(+6.41%)Amazon Rallies 7%, Apple and Microsoft Climb 5% as Big Tech Leads Post-Election Rebound10:02:35 AM ETJPM$345.02+7.10(+2.10%)How Will Automation and Kinexys Drive JPMorgan's Payments Growth?10:01:30 AM ETGS$912.62+16.77(+1.87%)The Goldman Sachs Group, Inc. (GS) is Attracting Investor Attention: Here is What You Should Know10:01:23 AM ETKO$94.72-0.07(-0.07%)CocaCola Company (The) (KO) Is a Trending Stock: Facts to Know Before Betting on It10:01:14 AM ETGILD$169.61+2.15(+1.28%)Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It10:01:13 AM ETWFC$85.52-0.01(-0.01%)Here is What to Know Beyond Why Wells Fargo & Company (WFC) is a Trending Stock10:01:11 AM ETABBV$285.02-0.95(-0.33%)Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?10:01:07 AM ETASML$1,511.78-40.00(-2.58%)ASML Holding N.V. (ASML) Is a Trending Stock: Facts to Know Before Betting on It10:01:05 AM ETQCOM$168.58+4.15(+2.52%)Options Corner: QCOM Signs SPCX Deal as Earnings Loom10:00:04 AM ETAMZN$269.07+18.29(+7.29%)Amazon Stock Fell After Earnings. Should Investors Be Worried?10:00:00 AM ETASML$1,511.78-40.00(-2.58%)Better AI Semiconductor Monopoly Stock: Taiwan Semiconductor vs. ASML9:55:00 AM ETAMD$490.12+6.29(+1.30%)AMD Just Doubled Its Own Long-Term Growth Target for 20279:54:15 AM ETWMT$128.68+3.84(+3.08%)As Holidays Approach, No One Cares About Amazon's Biggest Business9:45:51 AM ETQCOM$168.58+4.15(+2.52%)Qualcomm Shares Rise Wednesday: What's Going On?9:38:42 AM ETASM$4.58+0.32(+7.51%)ASM International: 1.4nm Could Keep The Growth Going9:36:39 AM ETAMD$490.12+6.29(+1.30%)Why I'm Not Worried About AMD Anymore (Rating Upgrade)9:30:38 AM ET

IMMX · NASDAQ

Immix Biopharma, Inc.

$7.64 -0.08 (-1.04%)

Company overview

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing tissue-specific therapeutics for oncology and inflammation in the United States and Australia. The company is developing IMX-110, which is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for colorectal cancers; and IMX-120, a tissue-specific biologic for ulcerative colitis and severe Crohn's disease. The company has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors using IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma was incorporated in 2012 and is headquartered in Los Angeles, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$633M
Employees
18
Headquarters
Los Angeles, CA
Website
immixbio.com
CEO
Ilya Rachman
Listed
December 16, 2021
P/E
-8.43
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$130,766
Operating income
-$36.1M
EBITDA
-$35.6M
Net income
-$35M
EPS
-$0.92
Total assets
$95.8M
Total debt
$1M
Earnings yield
-11.86%

Price chart

6.858.9911.1313.2815.42
IMMX 1D NASDAQ O7.33H7.80L7.17C7.72+0.46 (+6.34%)Vol871.87K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
IMMXImmix Biopharma, Inc. Press release Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026 GlobeNewswire
IMMXImmix Biopharma, Inc. Press release Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference GlobeNewswire
IMMXImmix Biopharma, Inc. Stock news Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study MarketBeat
IMMXImmix Biopharma, Inc. Press release Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock GlobeNewswire
IMMXImmix Biopharma, Inc. Stock news Immix Biopharma (NASDAQ:IMMX) Stock Jumps 4.1% – Should You Buy? Defense World
IMMXImmix Biopharma, Inc. Stock news Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript Seeking Alpha
IMMXImmix Biopharma, Inc. Press release Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock GlobeNewswire
IMMXImmix Biopharma, Inc. Press release Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relaps. GlobeNewswire
IMMXImmix Biopharma, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX GlobeNewswire
IMMXImmix Biopharma, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX PRNewsWire
IMMXImmix Biopharma, Inc. Legal IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law Business Wire
IMMXImmix Biopharma, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX GlobeNewswire
IMMXImmix Biopharma, Inc. Press release Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference GlobeNewswire
IMMXImmix Biopharma, Inc. Legal IMMX INVESTIGATION: Securities Fraud Investigation by Block & Leviton Could Allow Immix Biopharma Investors to Recover Losses Newsfile Corp
IMMXImmix Biopharma, Inc. Press release Immix Biopharma Investigated by the Portnoy Law Firm GlobeNewswire
IMMXImmix Biopharma, Inc. Legal IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc. GlobeNewswire
IMMXImmix Biopharma, Inc. Legal Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims Newsfile Corp
IMMXImmix Biopharma, Inc. Legal IMMX ALERT: Immix Biopharma Investigated for Securities Fraud Violations by Block & Leviton; Investors Should Contact the Firm GlobeNewswire
IMMXImmix Biopharma, Inc. Stock news Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High? Zacks Investment Research
IMMXImmix Biopharma, Inc. Stock news Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock GlobeNewswire
See more
FAQ

Questions about Immix Biopharma, Inc.

What does Immix Biopharma, Inc. do?
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing tissue-specific therapeutics for oncology and inflammation in the United States and Australia. The company is developing IMX-110, which is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for colorectal cancers; and IMX-120, a tissue-specific biologic for ulcerative colitis and severe Crohn's disease. The company has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors using IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma was incorporated in 2012 and is headquartered in Los Angeles, California.
What is IMMX's market cap?
Immix Biopharma, Inc. (IMMX) is a listed stock with a live quote. The latest market cap on this page is $633M.
Where is Immix Biopharma, Inc. headquartered?
Immix Biopharma, Inc. is headquartered in Los Angeles, CA.
How do I get IMMX news from the API?
Call GET /v1/news?tickers=IMMX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does IMMX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for IMMX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the IMMX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs